Market Overview

Celgene Could Achieve 2020 Targets, BTIG Upgrades To Buy

Celgene Could Achieve 2020 Targets, BTIG Upgrades To Buy
Related CELG
Celgene Shares Higher On Positive Crohn's Patient Data
Watch These 5 Huge Call Purchases In Monday Trade

Although Celgene Corporation’s (NASDAQ: CELG) financial targets for 2020 are higher than consensus expectations, the company may be able to achieve them through new commercial products, label expansion and M&A, BTIG’s Dane Leone said in a report. He upgraded the rating on the company from Neutral to Buy, while establishing the price target at $138.

Celgene has announced its 2020 revenue and EPS targets for 2020 at +$21 billion and +$13, representing upside to the consensus estimates of ~$20 billion and ~$12.47, respectively. Analyst Dane Leone considers the targets as achievable via new commercial products, label expansion and M&A.

Ozanimod Prospects

Pivotal trial data for Ozanimod for treatment of relapsing Multiple Sclerosis is expected to be released in 1H17, and could support approval in 2018. “The current ‘best-in-class’ S1P data-set, the +$17bn size of the market for MS drugs along with the +$3bn annual sales of Gilenya, all support our expectation for ~$1.5bn in Ozanimod sales during 2020E,” Leone wrote.

Other Prospects

The analyst expects data from the AUGMENT, RELEVANCE and ROBUST studies for Follicular Lymphoma and Diffuse Large B-Cell Lymphoma [DLBCL] to support additional Revlimid revenues of ~$1.1 billion by 2020. He added that phase 1 data from the CC-122 DLBCL Study is expected in 2H16 and could “represent a +$2.5 billion revenue opportunity for front-line use.”

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for CELG

Oct 2016JefferiesMaintainsBuy
Sep 2016CitigroupMaintainsBuy
Aug 2016BTIG ResearchUpgradesNeutralBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: btig Dane LeoneAnalyst Color Long Ideas Upgrades Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (CELG)

View Comments and Join the Discussion!